North America Soft Tissue Allografts Market Size and Forecast (2021

Description

List of Tables

The North America Soft Tissue Allografts Market is projected to grow significantly, with an expected market size of approximately US$ 2,942.7 million by 2031, up from US$ 1,764.2 million in 2024. This growth represents a compound annual growth rate (CAGR) of 7.6% from 2024 to 2031.

Executive Summary and Market Analysis

The soft tissue allografts market in North America is primarily divided into three regions: the United States, Canada, and Mexico. Several factors are driving the growth of this market. Notably, advancements in dental implant technologies have improved the effectiveness of soft tissue allografts in dental procedures. Additionally, the rising incidence of sports injuries, particularly those involving the anterior cruciate ligament (ACL), has led to an increased demand for allograft tissues used in ligament reconstruction surgeries. The aging population in North America also plays a crucial role in market expansion, as older adults are more prone to joint and bone disorders that often require surgical interventions. Furthermore, the region's well-established healthcare infrastructure and substantial healthcare spending facilitate the adoption of innovative surgical techniques, including the use of soft tissue allografts.

Strategic Insights

Market Segmentation Analysis

The North America Soft Tissue Allografts Market can be segmented based on type, application, and end user:

By Type: The market includes various types of allografts such as Cartilage Allografts, Tendon Allografts, Dental Allografts, Meniscus Allografts, Placental Tissue, and others. In 2024, Cartilage Allografts held the largest market share.
By Application: The applications of soft tissue allografts are categorized into Orthopedic, Dentistry, Wound Care, and others. Orthopedic applications dominated the market in 2024.
By End User: The end users of soft tissue allografts include Hospitals, Specialty Clinics, and others, with hospitals accounting for the largest share in 2024.

Market Outlook

The demand for soft tissue allografts is significantly influenced by sports-related injuries, particularly among athletes and physically active individuals. According to the National Safety Council, in 2023, approximately 3.7 million people in the US sought treatment in emergency departments for injuries. Notably, injuries related to exercise and exercise equipment saw an 8% increase from 2022 to 2023, rising from 445,642 injuries in 2022 to 482,886 in 2023. The highest injury rates were observed in the 15-24 age group, with males sustaining more injuries than females (276,377 males vs. 206,381 females). A staggering 90% of these injured individuals were treated in emergency departments.

The prevalence of injuries sustained during sports and physical activities has led to a heightened demand for soft tissue allografts, which are essential for repairing or replacing damaged tissues. When injuries are too severe for the body to heal naturally or through conventional treatments, soft tissue allografts become a viable solution for repairing or reconstructing the affected tissues. Since the 1980s, allografts have been routinely utilized in sports medicine. They are considered a crucial substitute for reconstructing torn menisci, deficient ligaments, and osteochondral defects during knee surgeries. These procedures allow for standardized grafts in reconstructive surgeries, ensuring consistency in graft diameter, integrity, shape, and reproducibility. Moreover, soft tissue allografts have emerged as an attractive alternative to autografts, offering benefits such as shorter operating times, increased efficiency, and reduced donor site morbidity. Consequently, the growth of the soft tissue allografts market can be attributed to the rising incidence of sports injuries and trauma.

Country Insights

The North America Soft Tissue Allografts Market is further segmented by country, with the United States, Canada, and Mexico being the primary regions. The United States holds the largest market share as of 2024.

In the US, a significant number of procedures involving soft tissue allografts are performed annually. For instance, a study published in 2024 titled "New Device Inspired by Python Teeth Doubles Strength of Rotator Cuff" indicates that over 600,000 rotator cuff procedures are conducted each year. Additionally, the American Orthopedic Society for Sports Medicine reports that between 100,000 and 250,000 ACL ruptures occur annually in the country. The increasing awareness of soft tissue injuries and their treatment among athletes has further emphasized the importance of addressing these injuries.

Company Profiles

Key players in the North America Soft Tissue Allografts Market include Integra LifeSciences Holdings Corp, Stryker Corp, Zimmer Biomet Holdings Inc, Organogenesis Inc., AbbVie Inc, Dentsply Sirona Inc, Smith & Nephew Plc, Conmed Corp, Arthrex Inc, and Axogen Corporation. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their product offerings and increase their market share.

Product Code: TIPRE00041994

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Soft Tissue Allografts Market Landscape

4.1 PEST Analysis

5. North America Soft Tissue Allografts Market - Key Market Dynamics

5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:

6. Soft Tissue Allografts Market - North America Market Analysis

6.1 North America Soft Tissue Allografts Market Revenue (US$ Million), 2024 - 2031
6.2 North America Soft Tissue Allografts Market Forecast and Analysis

7. North America Soft Tissue Allografts Market Revenue Analysis - by Type

7.1 Cartilage Allograft
- 7.1.1 Overview
- 7.1.2 Cartilage Allograft: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Tendon Allograft
- 7.2.1 Overview
- 7.2.2 Tendon Allograft: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.3 Dental Allografts
- 7.3.1 Overview
- 7.3.2 Dental Allografts: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.4 Meniscus Allografts
- 7.4.1 Overview
- 7.4.2 Meniscus Allografts: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.5 Placental Tissue
- 7.5.1 Overview
- 7.5.2 Placental Tissue: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

8. North America Soft Tissue Allografts Market Revenue Analysis - by Application

8.1 Orthopedic
- 8.1.1 Overview
- 8.1.2 Orthopedic: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Dentistry
- 8.2.1 Overview
- 8.2.2 Dentistry: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Wound Care
- 8.3.1 Overview
- 8.3.2 Wound Care: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

9. North America Soft Tissue Allografts Market Revenue Analysis - by End User

9.1 Hospitals
- 9.1.1 Overview
- 9.1.2 Hospitals: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Specialty Clinics
- 9.2.1 Overview
- 9.2.2 Specialty Clinics: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

10. North America Soft Tissue Allografts Market - Country Analysis

10.1 North America
- 10.1.1 North America Soft Tissue Allografts Market Revenue and Forecast and Analysis - by Country
  - 10.1.1.1 North America Soft Tissue Allografts Market Revenue and Forecast and Analysis - by Country
  - 10.1.2.2 United States: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
    - 10.1.2.2.1 United States: North America Soft Tissue Allografts Market Share - by Type
    - 10.1.2.2.2 United States: North America Soft Tissue Allografts Market Share - by Application
    - 10.1.2.2.3 United States: North America Soft Tissue Allografts Market Share - by End User
  - 10.2.3.3 Canada: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
    - 10.2.3.3.1 Canada: North America Soft Tissue Allografts Market Share - by Type
    - 10.2.3.3.2 Canada: North America Soft Tissue Allografts Market Share - by Application
    - 10.2.3.3.3 Canada: North America Soft Tissue Allografts Market Share - by End User
  - 10.3.4.4 Mexico: North America Soft Tissue Allografts Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
    - 10.3.4.4.1 Mexico: North America Soft Tissue Allografts Market Share - by Type
    - 10.3.4.4.2 Mexico: North America Soft Tissue Allografts Market Share - by Application
    - 10.3.4.4.3 Mexico: North America Soft Tissue Allografts Market Share - by End User

12 Industry Landscape

12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments

13 COMPANY PROFILES

13.1 Integra LifeSciences Holdings Corp
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Stryker Corp
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Zimmer Biomet Holdings Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Organogenesis Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 AbbVie Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Dentsply Sirona Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Smith & Nephew Plc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Conmed Corp
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Arthrex Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Axogen Corporation
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners